• Profile
Close

Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia

Infection and Drug Resistance Mar 17, 2018

Lee C, et al. - In a retrospective study on adults with bloodstream infection (BSI) caused by flomoxef-susceptible cefotaxime-resistant Enterobacteriaceae (CE), researchers investigated the efficacy of flomoxef compared with that of ertapenem. Findings revealed similar outcomes with the two regimens. However, ertapenem therapy was observed to be associated with a shorter hospitalization time in adults after CE BSI.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay